CN114127051A - 成纤维细胞生长因子受体激酶的抑制剂 - Google Patents

成纤维细胞生长因子受体激酶的抑制剂 Download PDF

Info

Publication number
CN114127051A
CN114127051A CN202080051864.XA CN202080051864A CN114127051A CN 114127051 A CN114127051 A CN 114127051A CN 202080051864 A CN202080051864 A CN 202080051864A CN 114127051 A CN114127051 A CN 114127051A
Authority
CN
China
Prior art keywords
optionally substituted
pharmaceutically acceptable
solvate
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080051864.XA
Other languages
English (en)
Chinese (zh)
Inventor
史蒂芬·W·卡尔多
约翰·泰霍纳斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinnaite Biopharmaceutical Co
Original Assignee
Jinnaite Biopharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinnaite Biopharmaceutical Co filed Critical Jinnaite Biopharmaceutical Co
Publication of CN114127051A publication Critical patent/CN114127051A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202080051864.XA 2019-05-17 2020-05-14 成纤维细胞生长因子受体激酶的抑制剂 Pending CN114127051A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962849534P 2019-05-17 2019-05-17
US62/849,534 2019-05-17
US201962907491P 2019-09-27 2019-09-27
US62/907,491 2019-09-27
PCT/US2020/032939 WO2020236524A1 (en) 2019-05-17 2020-05-14 Inhibitors of fibroblast growth factor receptor kinases

Publications (1)

Publication Number Publication Date
CN114127051A true CN114127051A (zh) 2022-03-01

Family

ID=73458745

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080051864.XA Pending CN114127051A (zh) 2019-05-17 2020-05-14 成纤维细胞生长因子受体激酶的抑制剂

Country Status (7)

Country Link
US (1) US20230174535A1 (https=)
EP (1) EP3969442A4 (https=)
JP (1) JP2022533939A (https=)
CN (1) CN114127051A (https=)
AU (1) AU2020278566A1 (https=)
CA (1) CA3139161A1 (https=)
WO (1) WO2020236524A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024109799A1 (zh) * 2022-11-22 2024-05-30 西藏海思科制药有限公司 一种嘧啶衍生物及其在医药上的应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
US11345681B1 (en) * 2020-06-05 2022-05-31 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
CN116096707A (zh) * 2020-06-05 2023-05-09 金耐特生物制药公司 成纤维细胞生长因子受体激酶的抑制剂
KR20240119095A (ko) * 2021-12-08 2024-08-06 킨네이트 바이오파마 인크. Fgfr 저해제의 고체 상태 형태
WO2023107870A1 (en) * 2021-12-08 2023-06-15 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
AU2024301095A1 (en) * 2023-07-26 2026-03-12 Khora Spv 1, Llc Treatment of cancer with a cdk inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103958512A (zh) * 2012-01-19 2014-07-30 大鹏药品工业株式会社 3,5-双取代炔基苯化合物及其盐
CN107406455A (zh) * 2015-03-31 2017-11-28 大鹏药品工业株式会社 3,5‑二取代的苯炔基化合物晶体
CN107698593A (zh) * 2016-08-09 2018-02-16 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
WO2018121650A1 (zh) * 2016-12-29 2018-07-05 南京明德新药研发股份有限公司 Fgfr抑制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168968B1 (en) * 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
GB0428082D0 (en) * 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
US7723336B2 (en) * 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007064931A2 (en) * 2005-12-02 2007-06-07 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
GB201503590D0 (en) * 2015-03-03 2015-04-15 Davis Adrian Topical formulation
US11221750B2 (en) * 2016-02-12 2022-01-11 Purdue Research Foundation Manipulating 3D virtual objects using hand-held controllers
US10685111B2 (en) * 2016-10-31 2020-06-16 Crowdstrike, Inc. File-modifying malware detection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103958512A (zh) * 2012-01-19 2014-07-30 大鹏药品工业株式会社 3,5-双取代炔基苯化合物及其盐
CN107406455A (zh) * 2015-03-31 2017-11-28 大鹏药品工业株式会社 3,5‑二取代的苯炔基化合物晶体
CN107698593A (zh) * 2016-08-09 2018-02-16 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
WO2018121650A1 (zh) * 2016-12-29 2018-07-05 南京明德新药研发股份有限公司 Fgfr抑制剂

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024109799A1 (zh) * 2022-11-22 2024-05-30 西藏海思科制药有限公司 一种嘧啶衍生物及其在医药上的应用

Also Published As

Publication number Publication date
AU2020278566A1 (en) 2021-12-23
WO2020236524A1 (en) 2020-11-26
EP3969442A4 (en) 2023-08-02
EP3969442A1 (en) 2022-03-23
US20230174535A1 (en) 2023-06-08
JP2022533939A (ja) 2022-07-27
CA3139161A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
CN114127051A (zh) 成纤维细胞生长因子受体激酶的抑制剂
JP6934261B2 (ja) Ｎ−（アザアリール）シクロラクタム−１−カルボキサミド誘導体、その製造方法および応用
US11667634B2 (en) Inhibitors of RAF kinases
CN101084217B (zh) 作为治疗性化合物的咪唑并[4,5-b]吡啶-2-酮和唑并[4,5-b]吡啶-2-酮化合物及其类似物
JP7034512B2 (ja) キナーゼ阻害剤としてのヘテロアリール化合物
CN113874381A (zh) Raf激酶的抑制剂
CN102459187A (zh) Janus激酶抑制化合物和方法
CN110546145B (zh) 一种氮杂芳基衍生物、其制备方法和在药学上的应用
US11814384B2 (en) Inhibtors of Raf kinases
CN115989231B (zh) 一种作为btk抑制剂的化合物及其制备方法与用途
TW202229269A (zh) Raf激酶抑制劑
TW202409036A (zh) Parg抑制劑
AU2021285974A1 (en) Inhibitors of fibroblast growth factor receptor kinases
TW202342018A (zh) Mek激酶抑制劑
JP2024500636A (ja) ベンゼンスルホンアミド誘導体およびその使用
CN118974039A (zh) 新型苯并噻吩衍生物及其作为bet抑制剂的用途
WO2023107870A1 (en) Inhibitors of fibroblast growth factor receptor kinases
CN116438179B (zh) 作为ret激酶抑制剂的吡唑衍生物
HK40064672A (en) Inhibitors of fibroblast growth factor receptor kinases
WO2023070053A1 (en) Inhibitors of raf kinases
CN118439991B (zh) 一类rbj小分子抑制剂
HK40114068A (zh) Raf激酶的抑制剂
WO2025032214A1 (en) Indazole compounds and azaindazole compounds as inhibitors of raf kinases
HK40063842A (en) Inhibitors of raf kinases
HK40061750A (en) Inhibitors of raf kinases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40064672

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220301